Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2022 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -140.3k | 99.02% |
| EBITDA | -2.77m | 63.27% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.43m |
Number of shares | 3.65m |
52-week high/low | €10.24 - €0.56 |
| Dividends | No |
Beta | 2.37 |
P/E ratio | -21.66 |
PEG ratio | -0.04 |
P/B ratio | -6.38 |
P/S ratio | 0.00 |
Company profile
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Name | BiondVax Pharmaceuticals ADR |
| CEO | Amir Reichman |
| Headquarters | Jerusalem,
Israel |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 11/05/2015 |
| Employees | 33 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | BVXV |
